Myeloid maturation arrest
Also known as: Development, Developed, Developing, Progression
Methodology & AI Transparency ⓘ
Myeloid maturation arrest Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as D75.89, Myeloid maturation arrest (also termed Development or Developed) falls under Blood & Anemia management, where B12/MMA/folate [Myeloid maturation arrest D75.89] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry D75.89: Myeloid maturation arrest is managed within Blood & Anemia (aka Development).
- 3 Typical cash cost range: Clinicians assessing Myeloid maturation arrest focus on primary platelet/megakaryocyte dysregulation in Myeloid maturation arrest (D75.89: or inherited/acquired coagulation) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Myeloid maturation arrest monitoring tracks Serum Ferritin & in Myeloid maturation arrest (D75.89: Transferrin Saturation) toward Ferritin 50–150 ng/mL; TSAT 20%–45% (D75.89).
Ask our AI Specialists anything about Myeloid maturation arrest
What Is Myeloid maturation arrest?
Designated in federal medical registries as D75.89, Myeloid maturation arrest (also termed Development or Developed) falls under Blood & Anemia management, where B12/MMA/folate [Myeloid maturation arrest D75.89] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
In Myeloid maturation arrest (D75.89), physiological disruption stems from primary platelet/megakaryocyte dysregulation in Myeloid maturation arrest (D75.89: or inherited/acquired coagulation), informing Anemia, Clotting & Blood Disorders protocols that track Vitamin B12, Folate in Myeloid maturation arrest (D75.89: & Reticulocyte Count) (B12 > 500 pg/mL; appropriate marrow response (D75.89)).
Common Symptoms & Clinical Signs
- • Presentation of Myeloid maturation arrest (D75.89): restless legs, ice in Myeloid maturation arrest (D75.89: craving)
- • Secondary Myeloid maturation arrest clinical sign: easy bruising, prolonged in Myeloid maturation arrest (D75.89: bleeding from minor)
- • Symptom flares in Myeloid maturation arrest correlating with Serum Ferritin & in Myeloid maturation arrest (D75.89: Transferrin Saturation) deviation outside Ferritin 50–150 ng/mL; TSAT 20%–45% (D75.89)
- • Functional blood & anemia impact requiring B12/MMA/folate [Myeloid maturation arrest D75.89] evaluation (D75.89)
Myeloid maturation arrest Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D75.89 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Ferritin & in Myeloid maturation arrest (D75.89: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D75.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Myeloid maturation arrest (D75.89: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D75.89) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Platelet Count & in Myeloid maturation arrest (D75.89: PT/INR / aPTT) | Platelets 150–400 x10^3/uL (D75.89) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Myeloid maturation arrest
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Reblozyl (Luspatercept) Reblozyl • RxCUI RXN-B59572711 | Erythroid Maturation Agent | 77% | $3.3100 | $ 246.82 /mo |
| Idarubicin Hydrochloride Idamycin Pfs • RxCUI 1791493 | Anthracycline Topoisomerase Inhibitor | 81% | $1.1000 | $ 53.05 /mo |
| Choriogonadotropin Alfa Ovidrel, Pregnyl • RxCUI 727505 | Gonadotropin | 94% | $485.3285 | $ 185.00 /mo |
| Hydroxyurea Droxia, Hydrea • RxCUI 197797 | Antimetabolite | 87% | $0.1836 | $ 8.23 /mo |
| Gemtuzumab Ozogamicin Mylotarg • RxCUI 1944701 | CD33-directed Immunoconjugate | 76% | $1.0100 | $ 49.41 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Myeloid maturation arrest)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid: What a 406-Participant Study Found There was no significant difference between treatments in secondary efficacy endpoints, reflecting a lack of clinical response. Leukemia research • 2024-05-15 • Phase III Randomized Trial | N = 406 | 93/100 | PMID 38499457 ↗ |
| New Insights on Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia:: What a 447-Participant Study Found Common any-grade side effects (≥10% incidence in any arm) were diarrhea (87.0% vs 32.9%), febrile neutropenia (52.8% vs 49.3%), and nausea (52.5% vs 31.5%). Blood advances • 2022-07-26 • Phase III Randomized Trial | N = 447 | 93/100 | PMID 35413116 ↗ |
| New Insights on Glasdegib plus intensive or non-intensive chemotherapy for untreated acute: What a 404-Participant Study Found The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Leukemia • 2023-10-15 • Phase III Randomized Trial | N = 404 | 93/100 | PMID 37604981 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of ferric carboxymaltose infusion in reducing anemia in Common side effects in the FCM arm included neutropenia (17%), hypophosphatemia (16%), and fatigue (15%). American journal of hematology • 2021-12-01 • Phase III Randomized Trial | N = 122 | 88/100 | PMID 34653287 ↗ |
| Can This Approach Help? Inside the Latest Research on Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute Limited survival benefit in the Japanese subgroup can be attributed to small patient numbers and to baseline imbalances observed between treatment arms, with more patients in the venetoclax plus low-dose cytarabine arm presenting. Japanese journal of clinical oncology • 2021-08-30 • Phase III Randomized Trial | N = 27 | 88/100 | PMID 34322703 ↗ |
Myeloid maturation arrest Patient Community & “People Like Me” Threads
Filter Myeloid maturation arrest community threads and patient logs by age, biological sex, dosage, and treatment duration.